Comparative Pharmacology
Head-to-head clinical analysis: KAITLIB FE versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAITLIB FE versus VOLNEA.
KAITLIB FE vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KAITLIB FE (levonorgestrel/ethinyl estradiol/ferrous fumarate) is a combined hormonal contraceptive. Levonorgestrel is a progestogen that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides cycle control. The added ferrous fumarate is an iron supplement to treat iron deficiency anemia.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
One tablet (norethindrone 1 mg and ethinyl estradiol 0.02 mg, with ferrous fumarate 35 mg) orally once daily for 28 days (21 active pills, 7 placebo/iron pills).
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically significant for once-daily dosing
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Renal: 40-60% as unchanged drug; biliary: 20-30% as metabolites; fecal: 10-20%
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive